Selskabets formål er markedsføring og salg af lægemidler og helseprodukter samt dermed beslægtet virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 96.9 mio. | 6.4 mio. | 52 mio. | 26.2 mio. | 16 | |
CVR: 39503778
Secondary names: Karo Pharma ApS, Trimb Denmark ApS
Previous names: Karo Pharma ApS
Compared to 410 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Companies in the same industry and area
CVR 33671245
CVR 40041796
CVR 40549676
CVR 43346814
CVR 19389006
Karine Chabanis ép. Martin joined the board
Egil Mølsted Madsen left the board
Karo Healthcare ApS demonstrates a positive financial trajectory, with revenue increasing from 64.3 million DKK in 2023 to 96.9 million DKK in 2025, reflecting a strong growth trend. Profitability has remained relatively stable, although it dipped slightly to 6.4 million DKK in 2025 from 6.9 million DKK in 2024, indicating potential margin pressures. The company's equity has significantly improved, rising from 4.4 million DKK in 2021 to 26.2 million DKK in 2025, which strengthens its financial position. As a player in the wholesale trade of pharmaceuticals and healthcare products, Karo Healthcare is well-positioned within its industry, although ongoing attention to profit margins will be essential for sustained growth.
AI-generated summary
companydata.dk